Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs. Rikhotso, M. C., Ledwaba, S. E., Ngandu, J. K., Mavumengwana, V., Kinnear, C. J., Warren, R., Potgieter, N., & Traoré, A. N. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease, 27(8):599–605, August, 2023. doi abstract bibtex SETTING: According to reports in South Africa, treatment failure rates for rifampicin-resistant TB (RR-TB) are significant and below the WHO target of ≥70%. HIV infection and the use of highly active antiretroviral therapy (HAART) influence how patients receiving anti-TB drugs respond to therapy. In the treatment of RR-TB, more recent medications, including bedaquiline, pretomanid and linezolid (BPaL), have shown promising results.OBJECTIVE: To assess treatment outcomes in RR-TB patients using BPaL and other second-line anti-TB drugs as recommended by the WHO in the South African population.DESIGN: The databases Medline, PubMed, Google Scholar and Embase were searched for studies between 2015 and 2022, which investigated BPaL outcomes in South Africa.RESULTS: Of the 27,259 participants, 21% were on bedaquiline, 1% were taking pretomanid and 9% were taking linezolid as part of their background regimen. About 68% of the patients were HIV-positive, with 59% of them taking HAART.CONCLUSION: Overall, 66% of patients taking BPaL drugs as part of their background regimen had favourable treatment outcomes. Additionally, patients with RR-TB who were HIV-positive and taking HAART while receiving BPaL drugs as part of a background regimen had improved treatment outcomes.
@article{rikhotso_favourable_2023,
title = {Favourable outcomes in {RR}-{TB} patients using {BPaL} and other {WHO}-recommended second-line anti-{TB} drugs},
volume = {27},
issn = {1815-7920},
doi = {10.5588/ijtld.22.0649},
abstract = {SETTING: According to reports in South Africa, treatment failure rates for rifampicin-resistant TB (RR-TB) are significant and below the WHO target of ≥70\%. HIV infection and the use of highly active antiretroviral therapy (HAART) influence how patients receiving anti-TB drugs respond to therapy. In the treatment of RR-TB, more recent medications, including bedaquiline, pretomanid and linezolid (BPaL), have shown promising results.OBJECTIVE: To assess treatment outcomes in RR-TB patients using BPaL and other second-line anti-TB drugs as recommended by the WHO in the South African population.DESIGN: The databases Medline, PubMed, Google Scholar and Embase were searched for studies between 2015 and 2022, which investigated BPaL outcomes in South Africa.RESULTS: Of the 27,259 participants, 21\% were on bedaquiline, 1\% were taking pretomanid and 9\% were taking linezolid as part of their background regimen. About 68\% of the patients were HIV-positive, with 59\% of them taking HAART.CONCLUSION: Overall, 66\% of patients taking BPaL drugs as part of their background regimen had favourable treatment outcomes. Additionally, patients with RR-TB who were HIV-positive and taking HAART while receiving BPaL drugs as part of a background regimen had improved treatment outcomes.},
language = {eng},
number = {8},
journal = {The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease},
author = {Rikhotso, M. C. and Ledwaba, S. E. and Ngandu, J.-P. K. and Mavumengwana, V. and Kinnear, C. J. and Warren, R. and Potgieter, N. and Traoré, A. N.},
month = aug,
year = {2023},
pmid = {37491748},
pmcid = {PMC10365554},
keywords = {Antitubercular Agents, Diarylquinolines, HIV Infections, HIV Seropositivity, Humans, Linezolid, Rifampin, Tuberculosis, Tuberculosis, Multidrug-Resistant, World Health Organization},
pages = {599--605},
}
Downloads: 0
{"_id":"2MYaSNkgzAF8MGBaN","bibbaseid":"rikhotso-ledwaba-ngandu-mavumengwana-kinnear-warren-potgieter-traor-favourableoutcomesinrrtbpatientsusingbpalandotherwhorecommendedsecondlineantitbdrugs-2023","author_short":["Rikhotso, M. C.","Ledwaba, S. E.","Ngandu, J. K.","Mavumengwana, V.","Kinnear, C. J.","Warren, R.","Potgieter, N.","Traoré, A. N."],"bibdata":{"bibtype":"article","type":"article","title":"Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs","volume":"27","issn":"1815-7920","doi":"10.5588/ijtld.22.0649","abstract":"SETTING: According to reports in South Africa, treatment failure rates for rifampicin-resistant TB (RR-TB) are significant and below the WHO target of ≥70%. HIV infection and the use of highly active antiretroviral therapy (HAART) influence how patients receiving anti-TB drugs respond to therapy. In the treatment of RR-TB, more recent medications, including bedaquiline, pretomanid and linezolid (BPaL), have shown promising results.OBJECTIVE: To assess treatment outcomes in RR-TB patients using BPaL and other second-line anti-TB drugs as recommended by the WHO in the South African population.DESIGN: The databases Medline, PubMed, Google Scholar and Embase were searched for studies between 2015 and 2022, which investigated BPaL outcomes in South Africa.RESULTS: Of the 27,259 participants, 21% were on bedaquiline, 1% were taking pretomanid and 9% were taking linezolid as part of their background regimen. About 68% of the patients were HIV-positive, with 59% of them taking HAART.CONCLUSION: Overall, 66% of patients taking BPaL drugs as part of their background regimen had favourable treatment outcomes. Additionally, patients with RR-TB who were HIV-positive and taking HAART while receiving BPaL drugs as part of a background regimen had improved treatment outcomes.","language":"eng","number":"8","journal":"The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease","author":[{"propositions":[],"lastnames":["Rikhotso"],"firstnames":["M.","C."],"suffixes":[]},{"propositions":[],"lastnames":["Ledwaba"],"firstnames":["S.","E."],"suffixes":[]},{"propositions":[],"lastnames":["Ngandu"],"firstnames":["J.-P.","K."],"suffixes":[]},{"propositions":[],"lastnames":["Mavumengwana"],"firstnames":["V."],"suffixes":[]},{"propositions":[],"lastnames":["Kinnear"],"firstnames":["C.","J."],"suffixes":[]},{"propositions":[],"lastnames":["Warren"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Potgieter"],"firstnames":["N."],"suffixes":[]},{"propositions":[],"lastnames":["Traoré"],"firstnames":["A.","N."],"suffixes":[]}],"month":"August","year":"2023","pmid":"37491748","pmcid":"PMC10365554","keywords":"Antitubercular Agents, Diarylquinolines, HIV Infections, HIV Seropositivity, Humans, Linezolid, Rifampin, Tuberculosis, Tuberculosis, Multidrug-Resistant, World Health Organization","pages":"599–605","bibtex":"@article{rikhotso_favourable_2023,\n\ttitle = {Favourable outcomes in {RR}-{TB} patients using {BPaL} and other {WHO}-recommended second-line anti-{TB} drugs},\n\tvolume = {27},\n\tissn = {1815-7920},\n\tdoi = {10.5588/ijtld.22.0649},\n\tabstract = {SETTING: According to reports in South Africa, treatment failure rates for rifampicin-resistant TB (RR-TB) are significant and below the WHO target of ≥70\\%. HIV infection and the use of highly active antiretroviral therapy (HAART) influence how patients receiving anti-TB drugs respond to therapy. In the treatment of RR-TB, more recent medications, including bedaquiline, pretomanid and linezolid (BPaL), have shown promising results.OBJECTIVE: To assess treatment outcomes in RR-TB patients using BPaL and other second-line anti-TB drugs as recommended by the WHO in the South African population.DESIGN: The databases Medline, PubMed, Google Scholar and Embase were searched for studies between 2015 and 2022, which investigated BPaL outcomes in South Africa.RESULTS: Of the 27,259 participants, 21\\% were on bedaquiline, 1\\% were taking pretomanid and 9\\% were taking linezolid as part of their background regimen. About 68\\% of the patients were HIV-positive, with 59\\% of them taking HAART.CONCLUSION: Overall, 66\\% of patients taking BPaL drugs as part of their background regimen had favourable treatment outcomes. Additionally, patients with RR-TB who were HIV-positive and taking HAART while receiving BPaL drugs as part of a background regimen had improved treatment outcomes.},\n\tlanguage = {eng},\n\tnumber = {8},\n\tjournal = {The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease},\n\tauthor = {Rikhotso, M. C. and Ledwaba, S. E. and Ngandu, J.-P. K. and Mavumengwana, V. and Kinnear, C. J. and Warren, R. and Potgieter, N. and Traoré, A. N.},\n\tmonth = aug,\n\tyear = {2023},\n\tpmid = {37491748},\n\tpmcid = {PMC10365554},\n\tkeywords = {Antitubercular Agents, Diarylquinolines, HIV Infections, HIV Seropositivity, Humans, Linezolid, Rifampin, Tuberculosis, Tuberculosis, Multidrug-Resistant, World Health Organization},\n\tpages = {599--605},\n}\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n","author_short":["Rikhotso, M. C.","Ledwaba, S. E.","Ngandu, J. K.","Mavumengwana, V.","Kinnear, C. J.","Warren, R.","Potgieter, N.","Traoré, A. N."],"key":"rikhotso_favourable_2023","id":"rikhotso_favourable_2023","bibbaseid":"rikhotso-ledwaba-ngandu-mavumengwana-kinnear-warren-potgieter-traor-favourableoutcomesinrrtbpatientsusingbpalandotherwhorecommendedsecondlineantitbdrugs-2023","role":"author","urls":{},"keyword":["Antitubercular Agents","Diarylquinolines","HIV Infections","HIV Seropositivity","Humans","Linezolid","Rifampin","Tuberculosis","Tuberculosis","Multidrug-Resistant","World Health Organization"],"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"http://bibbase.org/zotero/TBHostGen","dataSources":["csPxbBZ9RG8CqYnrf"],"keywords":["antitubercular agents","diarylquinolines","hiv infections","hiv seropositivity","humans","linezolid","rifampin","tuberculosis","tuberculosis","multidrug-resistant","world health organization"],"search_terms":["favourable","outcomes","patients","using","bpal","recommended","second","line","anti","drugs","rikhotso","ledwaba","ngandu","mavumengwana","kinnear","warren","potgieter","traoré"],"title":"Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs","year":2023}